Bruce F Bell
Examiner (ID: 11075)
Most Active Art Unit | 1741 |
Art Unit(s) | 1741, 1754, 1746, 1745, 2734, 1795, 1759, 1102 |
Total Applications | 2788 |
Issued Applications | 2338 |
Pending Applications | 153 |
Abandoned Applications | 297 |
Applications
Application number | Title of the application | Filing Date | Status |
---|---|---|---|
Array
(
[id] => 17432063
[patent_doc_number] => 20220059773
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-02-24
[patent_title] => NOVEL HETEROCYCLIC COMPOUND AND ORGANIC LIGHT EMITTING DEVICE COMPRISING THE SAME
[patent_app_type] => utility
[patent_app_number] => 17/274878
[patent_app_country] => US
[patent_app_date] => 2019-09-20
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 8296
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -8
[patent_words_short_claim] => 282
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17274878
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/274878 | NOVEL HETEROCYCLIC COMPOUND AND ORGANIC LIGHT EMITTING DEVICE COMPRISING THE SAME | Sep 19, 2019 | Pending |
Array
(
[id] => 15618719
[patent_doc_number] => 20200079764
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-03-12
[patent_title] => ISOXAZOLE ANALOGS AS FXR AGONISTS AND METHODS OF USE THEREOF
[patent_app_type] => utility
[patent_app_number] => 16/569819
[patent_app_country] => US
[patent_app_date] => 2019-09-13
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 18661
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => 0
[patent_words_short_claim] => 482
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16569819
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/569819 | Isoxazole analogs as FXR agonists and methods of use thereof | Sep 12, 2019 | Issued |
Array
(
[id] => 15634339
[patent_doc_number] => 10590147
[patent_country] => US
[patent_kind] => B1
[patent_issue_date] => 2020-03-17
[patent_title] => Spirooxindole-pyrrolothiazole heterocyclic hybrids
[patent_app_type] => utility
[patent_app_number] => 16/566851
[patent_app_country] => US
[patent_app_date] => 2019-09-10
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 10
[patent_figures_cnt] => 24
[patent_no_of_words] => 5231
[patent_no_of_claims] => 18
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 24
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16566851
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/566851 | Spirooxindole-pyrrolothiazole heterocyclic hybrids | Sep 9, 2019 | Issued |
Array
(
[id] => 15527075
[patent_doc_number] => 20200055843
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-02-20
[patent_title] => HETEROAROMATIC COMPOUNDS AS BTK INHIBITORS
[patent_app_type] => utility
[patent_app_number] => 16/555205
[patent_app_country] => US
[patent_app_date] => 2019-08-29
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 12833
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16555205
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/555205 | HETEROAROMATIC COMPOUNDS AS BTK INHIBITORS | Aug 28, 2019 | Abandoned |
Array
(
[id] => 15267243
[patent_doc_number] => 20190382355
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2019-12-19
[patent_title] => 1,3-Diaza-Spiro-[3.4]-Octane Derivatives
[patent_app_type] => utility
[patent_app_number] => 16/554847
[patent_app_country] => US
[patent_app_date] => 2019-08-29
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 24089
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -20
[patent_words_short_claim] => 1254
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16554847
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/554847 | 1,3-diaza-spiro-[3.4]-octane derivatives | Aug 28, 2019 | Issued |
Array
(
[id] => 19612150
[patent_doc_number] => 12161045
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2024-12-03
[patent_title] => Pyrromethene boron complex, light emitting element using same, display device, lighting device, color conversion composition, color conversion film, color conversion substrate, light source unit and display
[patent_app_type] => utility
[patent_app_number] => 17/267936
[patent_app_country] => US
[patent_app_date] => 2019-08-22
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 2
[patent_figures_cnt] => 4
[patent_no_of_words] => 20150
[patent_no_of_claims] => 18
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 472
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17267936
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/267936 | Pyrromethene boron complex, light emitting element using same, display device, lighting device, color conversion composition, color conversion film, color conversion substrate, light source unit and display | Aug 21, 2019 | Issued |
Array
(
[id] => 17014092
[patent_doc_number] => 11083711
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2021-08-10
[patent_title] => Amine prodrugs of pharmaceutical compounds
[patent_app_type] => utility
[patent_app_number] => 16/544166
[patent_app_country] => US
[patent_app_date] => 2019-08-19
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 5517
[patent_no_of_claims] => 4
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 222
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16544166
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/544166 | Amine prodrugs of pharmaceutical compounds | Aug 18, 2019 | Issued |
Array
(
[id] => 15454269
[patent_doc_number] => 20200039959
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-02-06
[patent_title] => NOVEL BENZIMIDAZOLE DERIVATIVE HAVING JNK INHIBITORY ACTIVITY AND USE THEREOF
[patent_app_type] => utility
[patent_app_number] => 16/544029
[patent_app_country] => US
[patent_app_date] => 2019-08-19
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 18946
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -6
[patent_words_short_claim] => 86
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16544029
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/544029 | Benzimidazole derivative having JNK inhibitory activity and use thereof | Aug 18, 2019 | Issued |
Array
(
[id] => 15930891
[patent_doc_number] => 20200157079
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-05-21
[patent_title] => IRE1 Small Molecule Inhibitors
[patent_app_type] => utility
[patent_app_number] => 16/543188
[patent_app_country] => US
[patent_app_date] => 2019-08-16
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 39015
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16543188
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/543188 | IRE1 small molecule inhibitors | Aug 15, 2019 | Issued |
Array
(
[id] => 17634984
[patent_doc_number] => 11345696
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2022-05-31
[patent_title] => Compounds and methods of treating or ameliorating an IL-1R-mediated disease or disorder using same
[patent_app_type] => utility
[patent_app_number] => 16/537897
[patent_app_country] => US
[patent_app_date] => 2019-08-12
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 10
[patent_figures_cnt] => 10
[patent_no_of_words] => 13658
[patent_no_of_claims] => 10
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 48
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16537897
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/537897 | Compounds and methods of treating or ameliorating an IL-1R-mediated disease or disorder using same | Aug 11, 2019 | Issued |
Array
(
[id] => 16961511
[patent_doc_number] => 20210213010
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-07-15
[patent_title] => TLR7/8 AGONISTS AND LIPOSOME COMPOSITIONS
[patent_app_type] => utility
[patent_app_number] => 17/262623
[patent_app_country] => US
[patent_app_date] => 2019-07-24
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 48709
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -46
[patent_words_short_claim] => 23
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17262623
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/262623 | TLR7/8 AGONISTS AND LIPOSOME COMPOSITIONS | Jul 23, 2019 | Pending |
Array
(
[id] => 17356675
[patent_doc_number] => 20220017471
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-01-20
[patent_title] => FUNCTIONALITY INDEPENDENT LABELING OF ORGANIC COMPOUNDS
[patent_app_type] => utility
[patent_app_number] => 17/260992
[patent_app_country] => US
[patent_app_date] => 2019-07-17
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 17187
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17260992
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/260992 | FUNCTIONALITY INDEPENDENT LABELING OF ORGANIC COMPOUNDS | Jul 16, 2019 | Pending |
Array
(
[id] => 17082176
[patent_doc_number] => 20210277182
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-09-09
[patent_title] => AMINE-BASED REACTION PRODUCTS AS FUNCTIONAL ADDITIVES
[patent_app_type] => utility
[patent_app_number] => 17/261692
[patent_app_country] => US
[patent_app_date] => 2019-07-17
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 25787
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17261692
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/261692 | AMINE-BASED REACTION PRODUCTS AS FUNCTIONAL ADDITIVES | Jul 16, 2019 | Pending |
Array
(
[id] => 15086219
[patent_doc_number] => 20190337920
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2019-11-07
[patent_title] => PPAR AGONISTS, COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF
[patent_app_type] => utility
[patent_app_number] => 16/510976
[patent_app_country] => US
[patent_app_date] => 2019-07-15
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 22938
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16510976
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/510976 | PPAR agonists, compounds, pharmaceutical compositions, and methods of use thereof | Jul 14, 2019 | Issued |
Array
(
[id] => 15422419
[patent_doc_number] => 10544122
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2020-01-28
[patent_title] => TLR7/8 antagonists and uses thereof
[patent_app_type] => utility
[patent_app_number] => 16/507870
[patent_app_country] => US
[patent_app_date] => 2019-07-10
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 95284
[patent_no_of_claims] => 4
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 43
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16507870
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/507870 | TLR7/8 antagonists and uses thereof | Jul 9, 2019 | Issued |
Array
(
[id] => 17170242
[patent_doc_number] => 20210323912
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-10-21
[patent_title] => MEROCYANINE CRYSTALLIZATION PROCESS
[patent_app_type] => utility
[patent_app_number] => 17/259538
[patent_app_country] => US
[patent_app_date] => 2019-07-09
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 8083
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17259538
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/259538 | Merocyanine crystallization process | Jul 8, 2019 | Issued |
Array
(
[id] => 17096804
[patent_doc_number] => 20210284595
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-09-16
[patent_title] => SPIROBIINDANE DERIVATIVES AND A PROCESS FOR PREPARATION THEREOF
[patent_app_type] => utility
[patent_app_number] => 17/257941
[patent_app_country] => US
[patent_app_date] => 2019-07-03
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 1920
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -8
[patent_words_short_claim] => 23
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17257941
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/257941 | Spirobiindane derivatives and a process for preparation thereof | Jul 2, 2019 | Issued |
Array
(
[id] => 17081981
[patent_doc_number] => 20210276987
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-09-09
[patent_title] => PHARMACEUTICAL AGENTS FOR USE IN SMOKING AND TOBACCO CESSATION
[patent_app_type] => utility
[patent_app_number] => 17/257160
[patent_app_country] => US
[patent_app_date] => 2019-07-03
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 28404
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -20
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17257160
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/257160 | PHARMACEUTICAL AGENTS FOR USE IN SMOKING AND TOBACCO CESSATION | Jul 2, 2019 | Pending |
Array
(
[id] => 15323925
[patent_doc_number] => 20200002292
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-01-02
[patent_title] => BENZOIMIDAZOL-1,2-YL AMIDES AS Kv7 CHANNEL ACTIVATORS
[patent_app_type] => utility
[patent_app_number] => 16/460449
[patent_app_country] => US
[patent_app_date] => 2019-07-02
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 20429
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -6
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16460449
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/460449 | Benzoimidazol-1,2-yl amides as Kv7 channel activators | Jul 1, 2019 | Issued |
Array
(
[id] => 17312944
[patent_doc_number] => 20210401992
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-12-30
[patent_title] => METABOLICALLY STABLE PRODRUGS
[patent_app_type] => utility
[patent_app_number] => 17/254517
[patent_app_country] => US
[patent_app_date] => 2019-06-26
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 16301
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -15
[patent_words_short_claim] => 66
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17254517
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/254517 | METABOLICALLY STABLE PRODRUGS | Jun 25, 2019 | Pending |